Ensysce Biosciences, Inc. — Investor Relations & Filings

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing solutions for severe pain relief, with a focus on stemming the prescription drug abuse epidemic. The company utilizes proprietary prodrug technology platforms to create safer prescription drugs. Its lead product candidate, PF614, is a next-generation opioid designed with Trypsin-Activated Abuse Protection (TAAP™) to deter abuse via injection or inhalation. PF614 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). Ensysce is also developing its Multi-Pill Abuse Resistance (MPAR®) technology, an overdose protection platform designed to prevent respiratory depression when multiple doses are consumed. The company's goal is to provide effective pain management while reducing the potential for misuse, abuse, and overdose.